EVALUATION OF THE EFFECT OF FAVIPIRAVIR ON MANAGEMENT PATIENT WITH COVID-19
Phase 3
Recruiting
- Conditions
- Coronavirus disease 2019 (COVID19).COVID-19, virus identifiedU07.1
- Registration Number
- IRCT20201028049175N1
- Lead Sponsor
- Arak University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 114
Inclusion Criteria
All of patients with COVID19 referred to Valiasr and Khansari hospital
All of patients in subgroup 3 of hospitalization
Exclusion Criteria
Patients that present allergic reaction to the drug
Patients with deterioration of symptomps after drug usage
Renal failure manifestation in patients
Heart failure manifestation in patients
Pregnancy
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method